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Abstract
A fundamental challenge to contemporary genetics is to distinguish rare missense alleles
that disrupt protein functions from the majority of alleles neutral on protein activities. High-
throughput experimental tools to securely discriminate between disruptive and non-
disruptive missense alleles are currently missing. Here we establish a scalable cell-based
strategy to profile the biological effects and likely disease relevance of rare missense vari-
ants in vitro. We apply this strategy to systematically characterize missense alleles in the
low-density lipoprotein receptor (LDLR) gene identified through exome sequencing of 3,235
individuals and exome-chip profiling of 39,186 individuals. Our strategy reliably identifies
disruptive missense alleles, and disruptive-allele carriers have higher plasma LDL-
cholesterol (LDL-C). Importantly, considering experimental data refined the risk of rare
LDLR allele carriers from 4.5- to 25.3-fold for high LDL-C, and from 2.1- to 20-fold for early-
onset myocardial infarction. Our study generates proof-of-concept that systematic function-
al variant profiling may empower rare variant-association studies by orders of magnitude.
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Author Summary
Exome sequencing has proven powerful to identify protein-coding variation across the
human genome, unravel the basis of monogenic diseases and discover rare alleles that con-
fer risk for complex disease. Nevertheless, two key challenges limit its application to com-
plex phenotypes: first, most alleles identified in a population are extremely rare; and
second, most alleles are neutral on protein activities. Consequently, association tests that
rely on enumerating rare alleles in cases and controls (termed rare variant association
studies, RVAS) are typically underpowered, as the many neutral alleles dampen signals
that arise from the few alleles that disrupt protein functions. Strategies to securely discrim-
inate disruptive from neutral variants are immature, in particular for missense variants.
Here we show that the statistical power of RVAS improves dramatically if variants are
stratified according to their in vitro ascertained functions. We establish scalable technolo-
gy to objectively profile the biological effects of exome-identified missense variants in the
low-density lipoprotein receptor (LDLR) through systematic overexpression and comple-
mentation experiments in cells. We demonstrate that carriers of LDLR alleles, which our
experiments identify as “disruptive-missense”, have higher plasma LDL-C, and that con-
sidering in vitro data may make it possible to reduce RVAS sample sizes by more than
2-fold.
Introduction
The rate by which sequencing studies in humans are unraveling genetic variants far outweighs
our ability to accurately evaluate which of these variants are of the highest relevance to human
health and disease [1]. This interpretative gap is considered a key impediment for the wider use
of genetics in clinical medicine [2–4], as it challenges sequencing-based diagnoses [5–7] and
risks misguiding medical interventions or reproductive decisions [8]. It further limits the statis-
tical power of sequencing studies in families or populations that aim to identify novel disease
genes [9, 10].
The vast majority of rare protein-coding alleles are considered to be neutral, i.e., they have
no or little impact on disease liabilities. Importantly, this overabundance of neutral compared
with damaging alleles creates a tremendous signal-to-noise problem for rare-variant associa-
tion studies (RVAS) [10] that rely on the aggregation of all or distinct classes of rare variants at
the gene level [11]. RVAS have recently allowed us to identify rare variation in the low-density
lipoprotein receptor (LDLR) as associated with early-onset myocardial infarction (MI) in the
population [12]. Importantly, however, association signals were driven by loss-of-function
(LoF) alleles that based on sequence could be unambiguously interpreted as protein-
inactivating, including nonsense, splice-site or indel frameshift alleles. Carriers of LoF alleles in
LDLR showed an 18.1-fold increased MI-risk as opposed to an only 1.7-fold increased risk in
carriers of missense alleles. As missense variants by far outnumber LoF variants across human
genes [12–14], it has been hypothesized that including disruptive-missense (i.e., missense vari-
ants that disrupt protein functions in the range of LoF variants, “missense LoF”), while ignor-
ing neutral alleles should considerably enhance the association signal and reduce the necessary
samples sizes needed to demonstrate association, by on average 2.5-fold [10]. However, mis-
sense variants are the most difficult class of variants to adequately predict a biological function
[15], particularly in genes under selective pressure like LDLR where the rate of neutral relative
to disruptive-missense alleles is expected to be high [10].
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Deleterious variation in LDLR is kept at low frequency as heterozygote carriers of mutant al-
leles show familial hypercholesterolemia (FH), characterized by a 2–3 fold elevation of plasma
low-density lipoprotein cholesterol (LDL-C) and premature coronary artery disease [16].
Among Europeans, 4–5% of individuals who suffer fromMI before the age of 60 are FH hetero-
zygotes [17]. LDLR is also paradigmatic for a dose-response relationship between gene and
function as homozygotes are more severely affected than heterozygotes, and mutations that im-
pair, but not completely abolish receptor activity tend to result in more moderately increased
LDL-C, later onset MI and better response to therapies [16]. Mutations can impact different ac-
tivities of the LDLR protein, including its biosynthesis, subcellular trafficking and capacity to
bind and internalize LDL [18], yet biochemical tests to characterize FH mutants are low-
throughput and not applied routinely in clinical care [19]. Importantly, LDLR is one of 56
genes in which the incidental detection of known or novel variants is recommended for subse-
quent medical clarification [20].
Here we establish an experimental strategy to systematically characterize the biological
functions of missense alleles identified through exome analysis of large clinical cohorts. We
demonstrate at the case of LDLR and MI that a combination of sequencing with systematic var-
iant-profiling in vitromarkedly improves the statistical power of RVAS.
Results
Rare missense alleles deflate association of low-density lipoprotein
receptor (LDLR) with plasma LDL-C and MI-risk
With the aim to identify rare missense alleles in LDLR that increase the risk for premature MI,
we leveraged the exomes of 1,716 cases with MI prior to age of 46 and 1,519 MI-free controls
[12] (see Fig. 1 for workflow of this study). Overall, 194 subjects carried rare LDLR alleles that
distributed on 12 clear LoF and 70 missense variants (S1 Table, Methods and S1 Spreadsheet).
The burden of LoF alleles associated rare variation in LDLR with LDL-C and MI-risk at ge-
nome-wide significance (p<1×10-8) [12]. However, the more abundant missense alleles alone
or in combination with LoF variants considerably deflated association signals (e.g., for LDL-C
from odds ratio (OR)=34.4 to 3.2 and 4.5, respectively) (Table 1, Tables S2–3). This is consis-
tent with a scenario where the signal of alleles that disrupt LDLR activity—LoF alleles together
with missense alleles of a similar impact as LoF alleles (termed “disruptive-missense” alleles)—
is swamped by the noise of neutral alleles. A-priori information to separate between these two
groups is scarce as an overlap of four frequently used computational prediction tools assign
equal proportions of LDLRmissense alleles as damaging (51%) and likely benign (49%), re-
spectively (S1 Table). Moreover, the rate of unique alleles (61%) in the studied at-risk cohort
matches that of non-MI reference cohorts (S1 Fig.), which further complicated identification of
disruptive-missense alleles from sequence data alone.
Establishment of a microscope-based approach to systematically profile
the function of LDLRmissense alleles
In order to distinguish disruptive from non-disruptive LDLRmissense alleles, we established a
workflow to profile the function of missense alleles in an unbiased, quantitative and high-
throughput manner in vitro. For this, we applied two complementary experimental strategies:
first, an “overexpression” approach where wildtype or mutated LDLR-GFP was transiently ex-
pressed in cultured cells; and second a “complementation” approach where the endogenous re-
ceptor was silenced with LDLR-siRNA, but receptor activities were reconstituted by co-
expressing siRNA-resistant wildtype or mutated LDLR-GFP (S2 Fig. and Methods). Since we
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assumed that complementation might have the potential to unmask effects that fail to be iden-
tified by testing overexpression alone, both approaches were applied in parallel. The efficiency
of LDL-uptake into GFP-positive and GFP-negative cells was quantified by multiparametric
analyses from images acquired using high-content automated microscopy as described [21, 22]
(S3 Fig. and Methods). Expectedly, wildtype LDLR stimulated LDL-uptake, as evidenced by an
increased internalization of fluorescent-labeled LDL into endosome-like compartments
(Fig. 2A). This effect vanished when LDLR carried the transport–deficient FH-mutation p.
G549D [18] that mislocalized the receptor to endoplasmatic reticulum (ER)-like membranes,
or the internalization-deficient “JD”-mutant p.Y828C [23] that arrested both, ligand and recep-
tor at the plasma membrane. Multiparametric analysis of the phenotypes obtained from a large
number of cells (Fig. 2B,C) demonstrated that our approach could identify and correctly de-
scribe functions of previously known LDLRmissense variants causing FH.
Functional characterization of rare LDLR alleles identified through
exome sequencing of 3,235 individuals uncovers disruptive-missense
variants
We applied this workflow to systematically test which of the rare LDLRmissense alleles re-
vealed by exome sequencing of our large population cohort disrupted LDLR function. System-
atic experimental analyses of LDL-uptake into cells assigned each missense variant a distinct
phenotypic profile that enabled conclusions on its mechanisms (Fig. 3A; S4 Fig. and S1 Spread-
sheet). Results from overexpression and complementation correlated well (for instance, r2 =
0.56 for parameter “total LDL signal”; Fig. 3B; S4 Table), thus validating most of each other’s
Figure 1. Workflow of this study to determine the functional impact of 70 rare missense variants on
LDLR protein activities and improve rare variant association testing for plasma LDL-C and the risk for
early-onset MI. Variants were identified through whole-exome sequencing of 3,235 individuals from the
Italian Study of Early-onset Myocardial Infarction (ATVB) cohort.
doi:10.1371/journal.pgen.1004855.g001
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findings. Overall, 14 missense variants strongly inhibited LDLR function, typically by reducing
LDL-uptake to 6–31% of the wildtype receptor, and were classified as “disruptive-missense”.
As an independent validation, we measured whether these variants also impacted total cellular
levels of free cholesterol, another phenotype that we have previously shown to vary dependent
on LDLR activity [22]. Indeed, all but one disruptive-missense variant not only reduced LDL-
uptake, but also free cholesterol levels to less than 50% of controls (Fig. 3C; S5 Table). The only
non-validated disruptive-missense variant p.D472Y, as well as two transport-inhibiting ER-as-
sociated mutants (p.N316S; p.P526S) reduced LDLR’-GFP protein expression, which indicated
an impact on either LDLR biosynthesis or turnover. Like most known FHmutants [18] the ma-
jority of disruptive-missense variants clustered in the apoB-ligand binding domain of LDLR
and was completely or partially retained in ER-like membranes (Fig. 3D; S5 Fig.). Another 10
variants were defined as of “unclear” functional significance, as they met some, but not all re-
quired significance criteria (see Methods). The remaining 46 variants were classified as “non-
disruptive”.
Carriers of LDLR alleles identified as disruptive-missense have higher
plasma LDL-C
We next compared our in vitro results to plasma LDL-C levels available for 2,152 of the indi-
viduals in our studied cohort. For 20 variants previously listed in four LDLR locus-specific da-
tabases as either causing FH or neutral, experimental data matched with clinical interpretation
in 95% of cases (S6 Table and Methods). Importantly, plasma LDL-C was significantly higher
in disruptive-missense (221mg/dl) than in non-disruptive (154mg/dl; p<1.36×10-5) and inter-
mediary to LoF LDLR allele carriers (275mg/dl) (Fig. 4A; relative to 135mg/dl in individuals
with two wild-type LDLR alleles [12]). As discussed further below, only few carriers of a respec-
tive variant class showed LDL-C levels outside the expected range.
Table 1. Association of a burden of rare variants in the low-density lipoprotein receptor (LDLR) gene with plasma low-density lipoprotein cholesterol (LDL-
C) levels and the risk for early-onset myocardial infarction.




P-value OR 95% CI
plasma LDL-C clear LoF 11 16 0.007 13 3 2×10-10 34.4 9.4–189.7
all missense 55 127 0.059 35 92 4×10-7 3.2 2.0–4.9
all missense + LoF 66 143 0.066 48 95 4×10-13 4.5 3.0–6.6
predicted as damaging 30 48 0.022 22 26 2×10-9 6.9 3.7–12.9
predicted as damaging + LoF 41 64 0.030 35 29 2×10-17 10.4 6.1–18.1
disruptive- missense 13 20 0.009 14 6 1×10-9 18.6 6.6–59.6
disruptive missense + LoF 24 36 0.017 27 9 6×10-19 25.3 11.3–61.8
pheno-type variants analyzed variant count allele count allele freq. MI case (n = 1,716) MI control (n = 1,519) P-value OR 95% CI
MI clear LoF 12 17 0.005 17 0 2×10-5 - 3.7-inf.
all missense 70 177 0.055 119 58 1×10-4 1.9 1.4–2.6
all missense + LoF 82 194 0.060 136 58 8×10-7 2.1 1.6–3.0
predicted as damaging 36 62 0.019 50 12 8×10-6 3.8 2.0–7.8
predicted as damaging + LoF 48 79 0.024 67 12 3×10-9 5.1 2.7–10.4
disruptive- missense 14 29 0.009 27 2 5×10-6 12.1 3.0–105.4
disruptive missense + LoF 26 46 0.014 44 2 2×10-10 20.0 5.2–169.9
doi:10.1371/journal.pgen.1004855.t001
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Considering in vitro data for rare-variant association testing refines the
risk of LDLR allele carriers for high LDL-C and MI by orders of magnitude
These results demonstrated that our strategy efficiently enriched for FH alleles and suggested
that considering experimental data might also enhance rare-variant association testing. For
this, disruptive-missense alleles were enumerated in cases and controls across the entire cohort
(Fig. 4B,C) and tested for association with LDL-C and MI. Indeed, collapsing only disruptive-
missense (instead of all LDLRmissense) alleles strongly increased odds ratios from 3.2 to 18.6
for association with LDL-C, and from 1.9 to 12.1 for association with MI-risk (Table 1, Tables
S2–3). Enumerating disruptive-missense together with LoF variants firmly established rare
variation in LDLR as associated with plasma LDL-C (p<6×10-19; OR = 25.3) and MI-risk
(p<2×10-10; OR = 20.0) on the population level. Consistent with a theoretically predicted
Figure 2. Systematic functional profiling of low-density lipoprotein receptor (LDLR) alleles. (A) LDLRmissense variants were functionally
characterized by monitoring cellular uptake of fluorescently-labeled LDL (DiI-LDL; red) into cells (see Methods). Shown are automatically acquired images of
HeLa-Kyoto cells transiently expressing siRNA-resistant full-length human wildtype LDLR linked to EGFP (LDLR’-GFP), empty GFP-control plasmid, or two
FHmutants known to inhibit transport (p.G549D; FH class-2) or endocytosis (p.Y828C; FH class-4) of the LDLR protein. Arrows denote GFP-positive cells.
Note the localization of FH mutants to different subcellular compartments. Bars = 15μm. (B)Graphs depict relative signal intensities of total DiI-LDL in
endosome-like subcellular compartments (total LDL signal; y-axis, in arbitrary units) plotted against total cellular GFP expression (x-axis, in arbitrary units) for
wildtype LDLR (LDLR’-GFP, upper panel) and indicated FH mutants. Each graph depicts results from a single experimental replica upon either
overexpression of the respective cDNA-construct (left graphs) or complementation settings (i.e., siRNA knockdown of endogenous LDLR followed by
reconstitution with indicated LDLR-GFP constructs; right graphs). Each dot represents one individual cell. Dashed vertical bars separate cells classified as
GFP-negative (left from bar) from cells defined as GFP-positive. Dashed horizontal lines in complementation setting indicate mean total LDL signal in control
siRNA-treated cells expressing endogenous LDLR. Cells where total LDL signal fell above this threshold (indicating over-compensation by LDLR’-GFP
expression) were not respected for quantifications (see Methods). (C) LDLR activity was measured with five phenotypic parameters: total LDL signal in
endosome-like compartments, LDL concentration, number (seg. number) and area (seg. area) of subcellular DiI-positive endosome-like structures, and
cellular GFP-expression. The heatmap represents means from all experimental replicas per variant under the overexpression setting. Red reflects reduced,
blue increased signal relative to wildtype LDLR’-GFP. Phenotypes meeting statistical criteria as described in Methods are framed in orange. Bar graph
depicts total LDL signal ±SD normalized to wildtype LDLR’-GFP.
doi:10.1371/journal.pgen.1004855.g002
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Figure 3. Cell-based functional profiling distinguishes disruptive from non-disruptive rare missense variants in the low-density lipoprotein
receptor (LDLR) gene as identified through exome sequencing of 3,325 individuals. (A) Rare LDLRmissense variants from exome sequencing of the
ATVB cohort were individually introduced into LDLR’-GFP, transiently expressed in HeLa-cells, and the impact on cellular uptake of fluorescently-labeled
LDL (DiI-LDL) was quantified for the indicated four parameters and GFP-expression. Shown are means from 3–4 independent experiments per variant
relative to wild-type LDLR’-GFP. Phenotypes (red, reducing; blue, increasing) meeting statistical criteria (p<0.05; deviation>1) are framed in orange.
Sytematic Rare Variant Profiling to Improve RVAS
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2.2- to 3-fold reduction in the number of samples needed to be sequenced [10], power simula-
tions suggested that through integration of experimental data sequencing of only 1,200–1,400
(instead of 3,000–4,000) cases and controls would be sufficient to associate rare variation in
LDLR with MI-risk at genome-wide significance (Fig. 4D). Notably, experimental data empow-
ered RVAS considerably more than functional prediction tools that correctly evaluated all 14
disruptive-missense variants as damaging, yet consistent with previous observations [24]
showed higher type-I-error rates (Table 1; S1 Table; S7 Table and Methods).
For individual low-frequency LDLR alleles, effects on plasma LDL-C and
cellular LDL-uptake correlate
Most missense alleles identified in sequencing studies are rare. At limited sample sizes RVAS
thus typically fall short on clarifying by how much any individual rare variant contributes to a
complex trait [10]. Conversely, one advantage of in vitro studies is that once a variant has been
observed in a population, variant frequencies do not matter. We aimed to test whether experi-
mental data could support genetics also for single variant association analyses. In order to in-
crease the number of observations per variant, we analyzed the function of 16 LDLRmissense
alleles that are represented on the Illumina HumanExome v1.0 SNP array (“exome-chip”) and
that were genotyped in 39,186 individuals characterized for LDL-C (Fig. 5; S7 Table and S1
Spreadsheet) [25]. Overall, effect sizes between genotyping and in vitro experiments correlated
well (r2 = 0.45). Importantly, the variants with the highest beta (p.E101K, p.P685L) most pro-
nouncedly inhibited LDL-uptake in cells, supporting our hypothesis that systematic experi-
mental data will not only be informative for gene-burden analyses, but also in clarifying by
how much individual rare and low-frequency variants contribute to genetic etiologies.
Discussion
Our study demonstrates that distinguishing disruptive from non-disruptive missense alleles in
a well-described disease gene (LDLR) through systematic functional characterization in vitro
can further our understanding how rare, potentially damaging genetic variation contributes to
common, complex (hypercholesterolemia; MI) as well as Mendelian disease (FH). Thus far, the
role of cell-based experiments in human genetics has either been to validate assumed associa-
tions between one to few variants and disease, or to better comprehend the mechanisms why
variants firmly identified through genetics are pathogenic [2]. Conversely, our study, together
with few previous studies [24, 26, 27], predicts that soon unbiased experiments will attain a
much more central role in human genetics that could extend to the very core of disease gene
discovery.
Optimizing RVAS by stratifying missense alleles according to their in vitro ascertained func-
tions may prove especially powerful to identify and validate genes under a high selective pres-
sure where disruptive-missense are swamped by neutral alleles and sample sizes needed for
Variants that significantly reduced LDL-uptake in3 DiI-LDL parameters, including total LDL signal, were classified as “disruptive-missense” (for details, see
Methods). OSD, O-linked sugars domain (exon15); TMD, transmembrane domain (exons16–17); CT, carboxy-terminus (exon18). (B) Comparison of mean
total DiI-LDL signal intensities within endosome-like intracellular compartments (“total LDL signal”) between the overexpression setting (ΔLDLR’-GFP only)
and a complementation setting (siRNA against endogenous LDLR together with ΔLDLR’-GFP) relative to wildtype LDLR’-GFP (wt, black circle) and GFP
control (GFP, open circle). Variants classified as “non-disruptive” failed to reach significance in any parameter under neither experimental setting. (C) For 14
variants classified as disruptive-missense, impact upon overexpression on cellular levels of free cholesterol (FC) was determined. Shown are means±s.d.
relative to wildtype LDLR’-GFP from 2–4 independent experiments. (D) Determination of subcellular localization of LDLR’-GFP disruptive-missense variants.
Shown are maximal projections of confocal stacks of representative cells transiently transfected with indicated mutants. Bar graphs reflect ΔLDLR’-GFP
levels onWestern Blots (shown in S5 Fig.; means from 2 experiments) of endoplasmic reticulum (ER; 120kDa) relative to post-ER (160kDa) form of the LDLR
protein relative to total wildtype LDLR as determined by ratiometric measurements. For each mutant, contribution of ER- relative to total LDLR’-GFP protein
are indicated in percent.
doi:10.1371/journal.pgen.1004855.g003
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Figure 4. Functions and distribution of LDLR rare missense alleles identified through exome
sequencing of 3,235 individuals. (A) Plasma LDL-C (in mg/dl) in LDLRmissense allele carriers (dots) from
the ATVB cohort according to functional category (for classification, see Methods). LoF, loss-of-function.
Means are indicated by horizontal bars. p-value was determined by 2-sided, 2-tailed Student’s t-test. (B, C)
Individual LDLRmissense variants identified through exome sequencing of indicated number of individuals
Sytematic Rare Variant Profiling to Improve RVAS
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association become enormous [10]. For LDLR, as a gene with an average endogenous mutation
rate, Zuk et al. [10] estimated 17% of missense variants as being disruptive, which is well in line
with the 20% we identified experimentally. On the other hand, our strategy may be less amena-
ble to very essential genes where modulation of cellular levels by overexpression or knockdown
is less well tolerated. Also, sensitivity of our approach may be limited for genes where the corre-
lation between measured phenotype and gene function is less direct than between LDLR levels
and LDL-uptake, or where the odds ratios of even disruptive alleles are small.
For LDLR, our binary classification of alleles as either disruptive or non-disruptive simpli-
fies the range of functional consequences that missense variants can exert on receptor activities
[16, 18]. For instance, the inclusion of only disruptive variants for association testing neglects
hypomorphic variants that reduce LDLR activity by only few percent. In our study, this is evi-
denced by slightly elevated odds ratios also in non-disruptive allele carriers. It thus can be ex-
pected that through segregation analyses in families, or through more sensitive in vitro
readouts, several such alleles will be identified as FH mutants in the future. Although the indi-
vidual effect of hypomorphic alleles on LDLR activity may be small and, consistent with previ-
ous assumptions [10], they in sum add only little power to association tests, future RVAS may
profit from counting in also hypomorphic alleles in form of adjusted functional weights.
An intriguing hypothesis is that in addition to rare variation in LDLR, further genetic or en-
vironmental factors contribute to increase LDL-C in some carriers of alleles that in our experi-
ments scored as non-disruptive. However, a thorough analysis of known common and rare
genetic risk factors from the exomes of 23 individuals with plasma LDL-C levels that did not
match expectations from our in vitro analyses did not reveal clear evidence for epistatic effects
(see paragraph Search for reasons of aberrant LDL-C in LDLR missense allele carriers in Meth-
ods). More carriers of the identical rare alleles, or an even stronger relationship between genetic
variant, intermediate and clinical phenotype than between LDLR, LDL-C and MI are needed to
exploit the full spectrum of information available from large-scale sequencing studies. More-
over, relationships between in vitro ascertained function and in vivo phenotypes are likely to
improve further when the analyzed cohorts can be stratified for important confounders, here,
for instance, intake of LDL-lowering medications [28], which was unavailable for this study.
For Mendelian genetics it is worthwhile to note that seven of the variants analyzed here
have recently been observed incidentally through clinical exome sequencing of individuals
[29, 30] and are listed as potentially requiring medical intervention [20]. Interestingly, howev-
er, based on our in vitro studies none of these variants is a strong candidate for causing FH. A
more comprehensive annotation of important disease genes through studies like ours together
with family-based segregation analyses may help to considerably precise health risks in the fu-
ture. Through generating scalable cell-based assays for relevant intermediate phenotypes and
statistical tools that better incorporate genetic with heterogeneous functional datasets, we ex-
pect that composite sequencing-biological studies will become invaluable to human genetics in
order to face the flood of novel variants from the ever increasing number of sequenced
genomes.
are depicted according to genomic position starting at the 5’end (top). The numbers next to each variant
represent the number of times the respective variant was observed in cases and controls, respectively, with
regard to plasma LDL-C levels (b) and early-onset myocardial infarction (MI; c). Colors in circles represent
indicated functional classes as determined either by an overlap of four bioinformatic prediction tools
(PolyPhen-2, SIFT, MutationAssessor and MutationTaster; see Methods) (“prediction”) or cell-based
experimental studies of LDL-uptake. Variants in bold have been observed in both, cases and controls.
(D) Power calculations for the number of sequenced individuals needed to reach exome-wide significance
(p<2.5×10-6, reflected by power = 1) for association with MI-risk when the indicated classes of rare LDLR
alleles are taken into account. For details, see Methods.
doi:10.1371/journal.pgen.1004855.g004
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Figure 5. Impact of individual LDLRmissense variants on cellular LDL-uptake correlates with single-
variant association results for plasma LDL-C in ~40,000 individuals. (A, B)Comparison of results from
cell-based functional profiling of LDL-uptake (overexpression and complementation) and single variant
association tests for 16 LDLRmissense variants represented on the exome-chip and identified by genotyping
39,186 individuals frommultiple cohorts. Shown are means from 3–4 independent experiments per variant
Sytematic Rare Variant Profiling to Improve RVAS
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Materials and Methods
Genetics analyses
Study cohorts. The Italian Genetic Study of Early-onset Myocardial Infarction (ATVB) is a Eu-
ropean case-control collection designed to study the genetics of MI-susceptibility [12, 31, 32].
Exome-sequenced MI cases (n = 1,716) include survivors of a first acute myocardial infarction
(defined as more than 30min resting chest pain accompanied by typical ECG and serum abnor-
malities) at an age of less than 46 years with angiographically documented coronary artery dis-
ease. Exome-sequenced MI controls (n = 1,519) were matched for age, sex, and geographical
origin and assessed for further MI-risk factors (S10 Table). Principle component analyses did
not indicate selection bias between cases and controls (S7 Fig.). For 2,152 subjects (66.5%),
plasma low-density lipoprotein cholesterol (LDL-C) at enrollment was available, among them
1,184 MI cases and 968 MI controls. Overall, 251 subjects showed hypercholesterolemia de-
fined as LDL-C above 190mg/dl (4.91mmol/l) (LDL cases) and according to Simon Broome
criteria [19, 33] a high likelihood for FH. For 1,901 subjects LDL-C was in the normal range or
only moderately elevated (<190mg/dl; LDL controls). As expected, high LDL-C was strongly
associated with increased MI-risk in this cohort [12].
Genotype data were obtained from a meta-analysis of 39,186 independent samples charac-
terized with the Illumina HumanExome v1.0 SNP array (“exome-chip”). Samples were from
individuals of European ancestry derived from 25 studies on the impact of rare and low-
frequency coding variation on plasma lipids [25].
Ethics statement. All analyses in this study conformed to the ethical guidelines of the 1975
Declaration of Helsinki in its crespective latest version. The study has been approved by an IRB
from the Broad Institute under protocol number 2013P001840.
Exome sequencing and exome-chip genotyping. Exome sequencing was performed at the
Broad Institute Genomics Platform as described previously [34]. Details on all specific steps for
reliable variant calling from raw sequence or exome-chip data, as well as performed quality
controls for the cohorts used in our study are provided in Do et al. [12] and Peloso et al. [25].
LDLR gene variant selection. LDLR nomenclature throughout the manuscript relates to
Homo sapiens low density lipoprotein receptor (LDLR) transcript variant 1 (NM_000527.4;
ENST00000558518/ Ensembl73) encoding a protein of 860 amino acids. Overall, 79 DNA se-
quence variants in LDLR were functionally characterized in this study (S7 Table and S1 Spread-
sheet) out of which 78 were identified through exome sequencing and/or exome-chip profiling
and one (p.Y828C) was selected from the literature. Based on available biochemical and clinical
information, two FH-mutants with firmly established pathogenic mechanisms were chosen as
controls, p.G549D [FH Genoa] as example for a transport-inhibiting (class-2) mutant [18] and
p.Y828C [FH JD-Bari] that prevents association of LDLR with clathrin-coated pits and its in-
ternalization into the endosomal system (class-4) [18, 35]. Exome sequencing of the ATVB co-
hort [12] identified a total of 82 rare coding variants in LDLR, distributing on 194 alleles. Of
these variants, 12 were clear loss-of-function (LoF), causing in 8 cases introduction of a pre-
term stop codon (p.Q33; p.Q102; p.E140; p.C155; p.R350; p.Y419; p.W533; p.Q770)
and in 4 cases disruption of splice-donor sites (19:11213463_G/A; 19:11224126_G/A;
19:11224439_G/A; 19:11227676_T/C; NCBI37). Consistent with markedly reduced LDLR ac-
tivity, LoF variants strongly associated with plasma LDL-C (Table 1; Fig. 4A; S3 Table and
relative to wild-type LDLR’-GFP. Phenotypes (red, reducing; blue, increasing) meeting statistical criteria as
described in Methods are framed in orange. Effect size (beta) is provided as the difference of means of
plasma LDL-C levels between variant carriers and non-carriers (in mg/dl).
doi:10.1371/journal.pgen.1004855.g005
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[12]) and were omitted from cell-based studies. All 70 ATVB LDLRmissense variants were se-
lected for in vitro functional characterization, and 69 comprehensively profiled as described
below (with the exception of p.V859M that due to its localization at the LDLR carboxy-
terminus failed repetitive cloning attempts). Forty-three (61%) of these missense variants were
present only once among the 6,470 ATVB chromosomes, corresponding to a minor allele fre-
quency (MAF) of 1.5×10-4. Twenty-five variants occurred in 2–7 study participants, and two
variants in 19 and 40 subjects, respectively (S1A Fig.). Apart from p.T726I with a MAF of
0.00618, all variants fulfilled our definition of being rare by showing a MAF of less than 0.005,
corresponding to one heterozygote carrier per 100 study participants. LDLR variants identified
in the ATVB cohort were complemented by 16 variants represented on the Illumina Huma-
nExome vs1.0 SNP array that were identified by genotyping 39,186 European subjects from di-
verse studies characterized for plasma LDL-C [25]. Seven variants (p.R237H; p.G269D; p.
E277K; p.G592E; p.E626K; p.P685L; p.R744Q) overlapped between both studies. Frequency
distributions of LDLR coding variants among participants of the NHLBI exome sequencing
project (ESP) (6,823 individuals; 13,646 chromosomes) (S1B Fig.) were downloaded from the
Exome Variant Server (http://evs.gs.washington.edu/EVS/; accessed October 2014).
Locus-specific a priori information. For all 79 variants that underwent functional charac-
terization in this study we systematically searched for availability of a priori clinical or func-
tional information. For this, four public databases retaining locus-specific information on
variation in LDLR were queried: the Universal LDLR mutation database (http://www.umd.be/
LDLR/) [36]; the LDLR LOVD database at University College London (http://www.ucl.ac.uk/
ldlr/) [37]; the NCBI ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar) [38]; and the
Human Gene Mutation Database (professional version) (www.hgmd.org) [39]. Information
from 111 publications that these databases referred to (S6 Table and Supplemental References)
allowed us to classify 19 LDLR variants as either previously validated FH mutant (n = 7), likely
benign (n = 5), or of unclear disease relevance (n = 7; including variants identified in com-
pound-heterozygous individuals in combination with a clear FH mutation). All but one FH
mutant (p.V523M [FH-Kuwait] that in homozygous fibroblasts was reported as associated
with 12–25% residual LDLR activity [40]) met our criteria for being “disruptive-missense” (see
below). Except for one variant (p.D118Y) for which disease relevance also after in vitro func-
tional testing remained unclear, all other previously observed variants were classified as non-
disruptive. Of four additional variants that in the LDLR LOVD database were listed as FH, but
that had not previously been validated in vitro, only one variant (p.C222Y) met our criteria as
disruptive-missense. Of 56 variants that were listed in HGMD with the phenotype hypercho-
lesterolemia, yet without functional evidence for this, our analyses classified 13 as disruptive-
missense.
Comparison to bioinformatics prediction tools. For each missense variant we determined
its likelihood to interfere with LDLR protein activity by applying four commonly used in silico
functional predicition tools under default settings: PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph2) [41], SIFT (http://sift.jcvi.org) [42], MutationAssessor (http://mutationassessor.org)
[43] and MutationTaster (http://www.mutationtaster.org) [44] (S1 Table). Different result cat-
egories of each algorithm were assigned distinct numerical values (PolyPhen-2: damaging/
probably damaging,-1; possibly damaging,0; benign,+1; SIFT: damaging,-1; tolerated,+1; Muta-
tionAssesor: high/medium:,-1; neutral/low,+1; MutationTaster: disease-causing,-1; polymor-
phism,+1). A summed composite score was calculated for each variant from the overlap of all
four prediction tools. A composite score of more than 1 was considered as likely benign, of 0 as
unclear and of less than-1 as likely FH. Overall, bioinformatics prediction tools classified 40 of
the 79 studied LDLR missense variants (51%) as FH-like, 7 (9%) as of unclear disease relevance
and 32 (40%) as likely benign (S7 Table).
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Association testing. Rare variant association tests were performed by enumerating all rare
LDLR alleles of a distinct class (clear LoF; all missense; bioinformatically predicted as damag-
ing; disruptive-missense; non-disruptive; and unclear) and by calculating association of the
burden of variants in cases and controls with plasma LDL-C and MI using Fisher’s exact
test (see also [12]) (Table 1, S2 Table). To estimate effect sizes (beta) for continuous levels of
LDL-C in the ATVB cohort (S3 Table), linear regression analysis was performed with LDL-C
(in mg/dl) as outcome variable, carrier status as independent variable, and sex and age as
covariates.
Power calculations for LDLR rare variant association with MI. Based on sequence data
from 3,325 ATVB participants, we performed sample size extrapolations for association signals
driven by the burden of rare LDLR variants of either LoF variant carriers alone, or LoF variant
carriers combined with carriers of variants identified as disruptive-missense. The relative risk
of a mutation carrier was assumed to be 5.0. Prevalence of MI was assumed as 0.05. Case:Con-
trol ratio was assumed as 1. The number of rare variants was extrapolated into 500,000 individ-
uals. One thousand simulations were performed at a given sample size with intervals of 200
samples (from n = 0–2,000), 400 samples (from n = 2,000–4,000) and 2,000 samples (from n =
4,000–20,000). Power reflects the percentage of simulations that reached genome-wide signifi-
cance (set at 2.5×10-6 to account for testing of ~20,000 genes) at a given number of samples.
Cell-based functional analyses
Cells and reagents. HeLa-Kyoto cells and their suitability for measuring the dynamics of LDL-
uptake and cellular levels and distribution of free cholesterol (FC) were described in our previ-
ous studies [21, 22]. DiI-LDL (Life Technologies), Filipin III (Sigma), Draq5 (Biostatus), Dapi
(Hoechst), 2-hydroxy-propyl-beta-cyclodextrin (HPCD) (Sigma), Lipofectamine 2000 (Invi-
trogen) and Oligofectamine (Invitrogen) were purchased from the respective suppliers.
cDNA cloning, siRNAs and site-directed mutagenesis. A sequence-verified cDNA-clone
encoding full-length human LDLR carboxy-terminally linked to EGFP was described previous-
ly to adequately reflect activities of the wild-type receptor [22]. To guarantee knock-down of
the mRNA encoding the endogenous receptor, but not the heterologously expressed LDLR-
GFP cDNA during complementation experiments, three silent mutations (c.A1053G, c.
C1056T and c.A1059G) were introduced at Wobble-bases within the 19-nucleotide consensus
sequence (CAGCGAAGATGCGAAGATA) of LDLR-siRNA s224006 (Applied Biosciences)
by site-directed mutagenesis (see below) using the following primer sequences:
5'-ctggtggcccagcgaaggtgtgaggatatcgatgagtgtca-3' (forward) and 5'-tgacactcatcgatatcctca-
caccttcgctgggccaccag-3' (reverse). LDLR-siRNA efficiently reduced levels of the endogenous
LDLR mRNA by ~30% and of the endogenous protein by ~75%, respectively, significantly re-
duced cellular LDL-uptake [22] and abrogated expression of LDLR-GFP. In contrast, levels of
the siRNA-resistant LDLR-GFP construct (termed LDLR’-GFP) were unaffected by siRNA-
treatment (S2A Fig. and [22]). Subcellular distribution and effect upon overexpression and
complementation on DiI-LDL uptake were indistinguishable between LDLR-GFP and LDLR’-
GFP (Fig. 2A; S2B Fig. and [22]). LDLR’-GFP served as a template for introduction of studied
missense variants using QuikChange Lightning Site-directed mutagenesis kit (Agilent) accord-
ing to the manufacturer’s instructions. Oligonucleotides for generating distinct LDLR variants
were designed using the QuikChange Primer design tool (Agilent), ordered fromMetabion
(Martinsried, Germany) and are listed in S11 Table. During complementation experiments,
siRNA s229174 (Silencer Select, Applied Biosystems) served as a non-silencing control siRNA.
Overexpression, complementation and biological assays. For overexpression analyses,
cells were seeded on glass coverslips in 12-well plates (Corning) at a density of 4×104 cells/well,
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cultured in DMEM (PAA)/2mM L-glutamine/10% FBS (Biochrom) for 24h at 37°C/5% CO2,
and fluid-phase transfected with 2μg cDNA/well using Lipofectamine2000 (Invitrogen) ac-
cording to manufacturer’s instructions. Assays to monitor cellular uptake of fluorescently-
labelled LDL (DiI-LDL) were performed as described in more detail in a previous publication
[21]. In brief, cells cultured in serum-free medium and exposed to 1% 2-hydroxy-propyl-beta-
cyclodextrin for 45min were labelled with 50μg/ml DiI-LDL (Invitrogen) for 30min at 4°C.
DiI-LDL uptake was stimulated for 20min at 37.5°C before washing off non-internalized dye
for 1min in acidic (pH 3.5) medium at 4°C, fixation, and counterstaining for nuclei (Dapi,
Draq5) and cell outlines (Draq5). For quantification of cellular cholesterol, cells were stained
with 50μg/ml Filipin III in PBS (from a stock-solution of 1mg/ml in di-methyl-formamide),
fixed, and counterstained with cell and nuclear marker Draq5. For complementation experi-
ments, cells were seeded at an identical density, cultured in DMEM (PAA)/2mM L-glutamine/
10% FBS (Biochrom) for 24h at 37°C/5% CO2, and fluid-phase transfected with 0.5μl/well of
30μM LDLR-siRNA (s224006) or non-silencing control siRNA (s229174) for 24h using Oligo-
fectamine according to manufacturer’s instructions. One day after siRNA transfection, cells
were co-transfected with GFP-cDNAs using Lipofectamine2000 as described above, and cul-
tured for another 24h before biological assays were performed and samples were prepared for
microscopic analysis. Overexpression experiments were performed in 3–5, rescue experiments
in 1–6 biological replicates per variant. Images were acquired automatically with identical base-
line settings from 30 different positions/sample on an Olympus IX81 automated microscope
using an UPlanApo 20×0,7NA objective and ScanR software vs. 2.1.0.15 (Olympus
Biosciences).
Image data analysis. All images were visually quality controlled using Image J 1.46r
(Wayne Rasband, National Institutes of Health, Bethesda) in order to exclude pictures of insuf-
ficient technical or biological quality (e.g., due to image acquisition out of focus or aberrant cell
density). Biological replicates for each variant analyzed were compared to several controls pres-
ent during each individual experiment. Each overexpression experiment included wild-type
LDLR’-GFP as a positive control as well as two negative controls, i.) a sample where cells ex-
pressed a construct encoding only EGFP without the receptor protein (“GFP-control”) and ii.)
a sample where cells were exposed only to transfection reagents, but not cDNA (“transfection-
control”). Each complementation experiment included four controls: cells transfected either
with i.) LDLR siRNA or ii.) negative control siRNA, but no cDNA, as well as two samples
where LDLR siRNA-treated cells were co-transfected with either iii.) LDLR’-GFP or iv.) GFP-
control cDNAs. Images were analyzed with customized pipelines based on Cellprofiler 2.0 soft-
ware (http://www.cellprofiler.org) [45]. Analysis strategy was adjusted from [22] and is out-
lined in S3 Fig. In brief, outlines of individual cells were approximated by stepwise dilation of
masks generated from images of Draq5 and/or Dapi (for LDL-uptake) stained cell nuclei.
Mean cellular GFP signal (“GFP-expression”) was quantified from background-subtracted im-
ages within areas defined as cells. Filipin (for FC) or DiI-signal (for LDL-uptake) was quanti-
fied from background-subtracted images within masks that reflected distinct intracellular
compartments resembling endosomes (for LDL-uptake) or lysosomes (for FC: see also [22]) as
identified by local adaptive thresholding. When cells or compartments exceeded a range of
pre-defined parameters (such as signal intensity or shape, minimal/maximal diameter, mini-
mum allowed distance to neighbouring mask or edge of the image) they were omitted from fur-
ther analysis to exclude for instance dividing or apoptotic cells. Mean cellular background
intensity in the GFP channel was determined from the transfection-control sample of each ex-
periment. Tabulated numeric results from image analyses were further processed with custom-
ized R-pipelines (R-Studio Inc. vs 0.97.336). Cells with GFP-intensities beneath the 97
percentile of this transfection control sample were defined as “GFP-negative”, and this
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threshold was applied to determine GFP-negative cells also from the other samples of a respec-
tive experiment. Conversely, cells were defined as GFP-expressing (“GFP-positive”) if cellular
GFP-signals exceeded this GFP-negative threshold by at least two-fold. Complementation ex-
periments were performed under a “rescue”, but not overexpression setting. Specifically, an
upper threshold was introduced for the Cy3 (DiI)-channel, and DiI-LDL uptake was quantified
only from the fraction of GFP-positive cells that showed less than 1.25-fold the mean “total
LDL signal” (see below) of cells in the transfection-control sample, or less than 5 times the
mean “total LDL signal” of cells treated with LDLR siRNA without concomitant cDNA trans-
fection, or cells co-transfected with LDLR-siRNA and GFP-control plasmid, respectively. A
justification for this upper threshold is provided by complementation experiments shown in
S2B Fig. that demonstrate that reduced DiI-LDL uptake in response to LDLR knockdown can
be fully complemented by co-expressing wild-type LDLR’-GFP at only 10–20% of its maximal
expression level. For LDL uptake experiments five parameters were quantified per cell: (i) total
DiI signal intensity within intracellular endosome-like segments (“total LDL signal”), (ii) mean
DiI signal intensity within segments per cell (“LDL concentration”), (iii) number of individual
segments within cell masks (“seg. number”), (iv) summed area of all segments within cell
masks (“seg. area”), and (v) mean cellular GFP signal intensity (“GFP-expression”).
Statistical analysis of imaging data. For each parameter, means were calculated from all
cells per image, and cells were classified as either GFP-positive or GFP-negative. Results from
different images of the same biological replicate were averaged, and the ratios of GFP-positive
relative to GFP-negative cells were determined. A minimum of 25 GFP-positive cells per vari-
ant was required to be considered as independent experimental replicate. Results from different
biological replicates were then averaged and compared to outcomes for LDLR’-GFP. Impact of
a variant on a distinct parameter was considered as significantly different from wildtype
LDLR’-GFP when a paired, two-tailed Student’s t-test resulted in p-values of less than 0.05 and
a “deviation value” (a z-score-like measure described in detail in [22]) for parameter total LDL-
signal was larger than 1. A variant was categorized as “disruptive-missense” (i.e., severely dis-
rupting LDLR activity as would be expected from an LoF-mutant) if under the overexpression
setting “total LDL signal” as well as at least two other parameters reached significance. Under
the complementation setting, significance in the parameter “total LDL signal” was regarded as
sufficient to validate a variant identified as “disruptive-missense” under the overexpression set-
ting. In order to be classified as “non-disruptive”, none of the eight DiI-LDL parameters quan-
tified from overexpression and complementation settings was allowed to reach significance. A
variant was classified as of “unclear” functional significance if it met neither criteria for catego-
ry “disruptive-missense” nor “non-disruptive”. To test for possible interdependence of mea-
sured four DiI-LDL parameters, pairwise Pearson’s correlation values were calculated across
the entire dataset (comprising 79 different variants plus wildtype LDLR’-GFP; S7 Table). Con-
sistent with our expectations and the literature (see also [22]), parameters “total LDL signal”,
“LDL concentration”, “seg. number” and “seg. area” correlated well, both among each other as
well as between overexpression and complementation settings, reflecting a high reproducibility
of individual results (S4 Table).
For measuring the impact of disruptive-missense variants on free cholesterol (FC) levels,
total filipin signal intensities from lysosome-like intracellular areas were quantified as de-
scribed [22] from cells cultured and analysed in 96-well plates. Variants that significantly af-
fected cellular FC were determined from the ratio of signal intensities in GFP-positive relative
to GFP-negative cells according to identical significance criteria as described above (apart from
p.N316S for which no significance could be determined as it reached the minimal number of
required GFP-positive cells in only one out of four biological replicates).
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Secondary experimental analyses
Determination of LDLR protein levels. For quantification of LDLR protein levels by Western
Blot (Fig. 3D, S2 and S5 Figs.), HeLa-Kyoto cells co-transfected with cDNAs and siRNAs as de-
scribed above were lysed in 40μl SDS-loading buffer and subjected to immunoblotting with
anti-LDLR (Cayman Chemicals), anti-GFP (Roche) and anti-actin (Sigma). Signal intensities
of lanes representing 120kDa and 160kDa isoforms of LDLR protein were quantified from
background subtracted images using Image J 1.46r (Wayne Rasband, National Institutes of
Health, Bethesda) and normalized to levels of beta-actin.
Determination of ΔLDLR’-GFP subcellular localization. Subcellular localization of
LDLR’-GFP variants identified as disruptive-missense were re-analyzed at higher resolution
using a Zeiss LSM780 laser-scanning confocal microscope using a 63x objective. Assignment of
individual variants to different FH-mutant classes was based on i.) phenotypic effects on DiI-
LDL uptake, ii.) GFP expression level; and iii.) degree of localization to endoplasmatic reticu-
lum-like relative to endosome-like structures or the plasma membrane as determined visually.
Search for reasons of aberrant LDL-C in LDLRmissense allele carriers
Twenty-three LDLRmissense allele carriers from the exome-sequenced cohort (Fig. 1) showed
plasma LDL-C levels that did not match expectations from in vitro analyses. For instance, in
five carriers of disruptive-missense alleles that all showed early-onset MI, LDL-C was below
190mg/dl. Besides the unlikely possibility for reduced penetrance of heterozygous FH [46] and
MI for other causes, a reasonable explanation for this could be that these individuals received
LDL-lowering therapies (e.g., statins) at study inclusion. As this information was unavailable to
us, precision of the type I error rate for our cell-based analyses is difficult, although it can be as-
sumed as likely small. Of higher relevance is why some carriers of LDLR alleles classified as
non-disruptive still showed elevated plasma LDL-C and/or MI, although this is in part this jus-
tified by the use of strict sensitivity thresholds that excluded potentially hypomorphic variants
from association testing (see Discussion).
It is tempting to speculate that additional genetic variants could have their share in increas-
ing LDL-C in some non-disruptive LDLR allele carriers. One reason for this could be com-
pound-heterozygosity for more than one rare variant at the LDLR locus. For instance, we
identified one carrier of the most likely neutral variant p.G20R as also carrying the FH mutant
p.G549D, and the latter variant is much more likely to explain that individual’s plasma LDL-C
of 218mg/dl. Likewise, compound-heterozygosity for two hypomorphic variants could impair
receptor activities in the range of a classic FH-mutant. This is best exemplified by another
ATVB individual compound-heterozygous for neutral variants p.L432V and p.Y465N and
LDL-C of 309.4mg/dl.
Also, increasing evidence supports a di- or polygenic contribution to the regulation of plas-
ma lipid levels and MI-risk [47–49], and alterations in other genes might explain elevated
LDL-C in non-disruptive allele carriers, or unexpectedly low LDL-C in disruptive allele carri-
ers. To test the hypothesis that common risk variants might modify LDL-C levels in these indi-
viduals, we calculated polygenic risk scores for variation in LDL-C according to [48] based on
20 lead SNPs from genome-wide association studies for plasma lipids [47] that were repre-
sented on the exome chip (S8 Table). Exome chip genotypes were available for 2,433 ATVB
study participants. Risk scores relative to plasma LDL-C for all participants are plotted in S6
Fig. In the 23 individuals with unexpectedly low or high LDL-C we did not observe a major
contribution of 20 common risk variants when this subcohort was compared to the rest of the
ATVB cohort.
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We also analyzed these 23 individuals for the presence of rare coding variation in 12 further
genes linked to Mendelian causes of abnormal plasma LDL-C (ABCG5, ABCG8, ANGPTL3,
APOA5, APOB, APOC3, APOE, LDLRAP1, LIPA,MTTP, NPC1L1 and PCSK9). This produced
a total of 21 rare and low-frequency protein-sequence altering variants that distributed over 10
genes (S9 Table). Clinical significance of these variants was evaluated based on information
from locus-specific FH databases (for ABCG5, ABCG8, APOB, LDLRAP1 and PCSK9), the
Exome Variant Server, ClinVar and HGMD. Only a single variant (p.R238W in LDLRAP1)
present in a heterozygous state in two of the 23 individuals had previously been reported from
patients with autosomal-recessive FH. However, based on an allele frequency of 0.048 in Euro-
peans and because association of this variant with LDL-C across the ATVB cohort, although
indicative, does not yet reach genome-wide significance (p<0.00037; Fisher’s exact test), the
contribution of this variant to LDL-C levels in the two LDLR variant carriers that also carry
this LDLRAP1 variant remains unclear. One rare variant in APOE (p.G145D) is described as
benign polymorphism. No database or literature data is available on the other 19 variants iden-
tified, and none has yet been characterized in vitro.
Supplemental data description
Supplemental Data contains eleven Supplemental Tables, seven Supplemental Figures, one
Supplemental Spreadsheet, and Supplemental References.
Web resources
Exome Variant Server, http://evs.gs.washington.edu/EVS/; Human Gene Mutation Database,
http://www.hgmd.org; LDLR UCL LOVD database, http://www.ucl.ac.uk/ldlr/; MutationAs-
sessor, http://mutationassessor.org; MutationTaster, http://www.mutationtaster.org; NCBI
ClinVar database, http://www.ncbi.nlm.nih.gov/clinvar; PolyPhen-2, http://genetics.bwh.
harvard.edu/pph2/; SIFT, http://sift.jcvi.org; Universal LDLR mutation database, http://www.
umd.be/LDLR/
Accession numbers
Data, including LDLR sequence data and functional annotations, will be available for download
from the NCBI ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/) under accession
numbers SCV000189524—SCV000189592 and SCV000189619—SCV000189628.
Supporting Information
S1 Fig. Frequency distribution and predicted mutational effect of LDLRmissense alleles in the
ATVB and NHLBI-ESP cohorts. Shown are frequency distributions of LDLRmissense alleles
discovered through exome sequencing of (A) 6,650 chromosomes of the Italian Genetic Study of
Early-onset Myocardial Infarction (ATVB) cohort and (B) 13,646 chromosomes of the NHLBI
exome sequencing project (ESP) study cohort. Mutational impact was estimated from the over-
lap of four bioinformatic prediction tools as detailed in Methods. Note that 43 out of 70 (61%)
variants in ATVB and 48 of 80 (60%) variants in NHLBI-ESP occur in only one single partici-
pant of the respective study cohort, and that the number of variants predicted as “damaging”
(red) almost equals the number of variants predicted as “neutral” (grey; unclear, yellow).
(EPS)
S2 Fig. Efficiency of LDLR knockdown, overexpression and complementation. (A)HeLa-
Kyoto cells were transfected with indicated GFP-labelled cDNAs and siRNAs as described in
Methods and subjected to Westen Blot for GFP, LDLR and beta-actin. Note that LDLR’-GFP
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encodes for wildtype LDLR protein, but is rendered insensitive to knockdown by LDLR-siRNA
through silent mutations at the siRNA-binding site. (B) DiI-LDL uptake as reflected by param-
eter “total LDL signal” (see Methods) in HeLa-Kyoto cells expressing indicated cDNAs and
siRNAs. Signal intensities were normalized to cells treated with transfection reagents only. For
LDLR’-GFP (blue-shaded columns), quantifications were performed in bins from cells below
the indicated upper thresholds (in %) of maximal GFP expression in a sample. In order to ex-
clude cells overcompensating the endogenous LDL-uptake, only those GFP-positive cells were
considered for quantifications during the systematic complementation experiments in this
study where “total LDL signal” did not exceed an upper threshold of 1.25-fold the mean “total
LDL signal” of cells in the “transfection control” samples, or showed less than 5 times the mean
“total LDL signal” of cells co-transfected with LDLR-siRNA and GFP-control cDNA (as indi-
cated here by dashed red line). Shown are means±s.d. from 18–25 independent experiments.
(EPS)
S3 Fig. Pipeline for automated multi-parametric image analysis of LDL-uptake. Shown are rep-
resentative images acquired by automated fluorescence microscopy during LDLR variant pro-
filing together with corresponding segmentations generated for image analysis. For quantifying
cellular LDL-uptake, GFP-cDNA or control plasmid transfected HeLa-Kyoto cells were ex-
posed to fluorescent DiI-LDL for 20min at 37°C, fixed and stained for cell nuclei (Dapi) or cell
outlines (Draq5). Masks representing nuclei, cells and endosome-like compartments were gen-
erated using CellProfiler, and DiI-LDL and GFP phenotypic readouts were quantified as de-
tailed in Methods. Bar = 20μm.
(EPS)
S4 Fig. Subcellular localization and effect on cellular LDL uptake of LDLRmissense variants
analyzed in this study. HeLa-Kyoto cells expressing LDLR’-GFP constructs carrying indicated
variants identified through exome sequencing of the ATVB cohort were cultivated in serum-
free medium, exposed to 1% hydroxypropyl-beta-cyclodextrin for 45min, and cellular uptake
of DiI-LDL was monitored for 20min at 37.5°C before fixation and preparation for microscopy.
Automatically acquired images of randomly selected GFP-positive and neighboring cells are
shown for each of the 70 variants studied. Heatmaps indicate means of the four parameters ap-
plied to assess LDL-uptake (for details, see S3 Fig. and Methods). Numbers reflect percent of
GFP positive cells (“GFP expression”). WT, wildtype LDLR’-GFP. Bar = 15μm.
(EPS)
S5 Fig. Disruptive-missense variants reduce LDLR protein levels and shift subcellular distribu-
tion towards the endoplasmic reticulum. Lysates of HeLa-Kyoto cells expressing LDLR’-GFP
constructs carrying indicated disruptive-missense variants were immunoblotted for EGFP and
beta-actin. Blots displayed served for ratiometric measurements of ER- relative to post-ER
form of the LDLR protein shown in Fig. 3D.
(EPS)
S6 Fig. A polygenic contribution by common LDL-C risk alleles does not explain unexpected
plasma LDL-C levels in ATVB LDLR variant carriers. For each ATVB participant genotyped
by exome-chip (n = 2,433), LDL-C specific gene scores were calculated according to [30] based
on the weighted sum of 20 common LDL-C raising risk alleles identified through the Global
Lipid Genetics Consortium (GLGC) [48]. Carriers of LDLR variants identified as “disruptive-
missense” in this study, but unexpectedly low LDL-C are highlighted in green, carriers of vari-
ants classified as “non-disruptive”, but high LDL-C in red (light red, “disruptive-missense” car-
riers with LDL-C>190mg/dl).
(EPS)
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S7 Fig. Principle component analysis reflects equal population structure between cases and
controls. Shown are principal component analysis blots to visualize the distribution of two ran-
domly chosen parameters (PC1, PC2; see S10 Table) between cases and controls in the ATVB
cohort (n = 3,235 individuals) for (A) plasma LDL-C levels (with cases defined as showing
LDL-C>190 mg/dl) and (B) MI status.
(EPS)
S1 Table. Comprehensive list, allele frequencies and predicted function of LDLR missense vari-
ants discovered by exome sequencing of 3,325 participants of the ATVB study.
(DOCX)
S2 Table. Association of a burden of rare variants in LDLR with plasma LDL-C levels and MI-
risk for variants classified as non-disruptive and unclear.
(DOCX)
S3 Table. Quantitative estimates of effect sizes (beta) based on continuous levels of LDL-C for
the displayed burdens of LDLR variants.
(DOCX)
S4 Table. Pearson’s correlations between analyzed parameters in LDL-uptake overexpression
versus complementation experiments.
(DOCX)
S5 Table. Impact of LDLR variants functionally classified in this study as disruptive-missense
on free cholesterol (FC) as visualized by Filipin.
(DOCX)
S6 Table. A priori information from locus specific databases and the literature on putative dis-
ease relevance on all 79 LDLR missense variants functionally characterized in this study.
(DOCX)
S7 Table. Comparative phenotypes for all LDLRmissense variants functionally analyzed in
this study.
(DOCX)
S8 Table. Common variants used to determine polygenic risk scores for association with plas-
ma LDL-C.
(DOCX)
S9 Table. Rare and low-frequency coding variants identified in 12 Mendelian lipid disease
genes among 23 LDLR variant carriers with unexpected high or low plasma LDL-C.
(DOCX)
S10 Table.Distribution of MI risk factors between ATVB MI cases and controls (means).
(DOCX)
S11 Table. Primer sequences for site-directed mutagenesis of LDLR’-GFP.
(DOCX)
S1 Spreadsheet. Comprehensive results for all 79 LDLRmissense variants functionally charac-
terized in this study by overexpression and complementation for a role on cellular LDL-uptake.
(XLSX)
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